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Abstract Transcriptional regulation may be important for
L-type Ca2+ channel K1C subunit (Cav1.2) gene expression. In
this study, we found two human Cav1.2 isoforms, one strongly
and selectively expressed in heart and the other with apparently
ubiquitous expression. The promoter for the cardiac isoform has
an ‘initiator’ sequence, and is active in neonatal cardiomyocytes
but not in cardiac ¢broblasts, H9C2 cells, human aorta-vascular
smooth muscle and HEK293 cells. The promoter for the ubiq-
uitously expressed isoform is of the ‘housekeeping’ type and is
active in all cell types examined. These data indicate speci¢c
expression patterns of two human Cav1.2 isoforms under the
control of distinct 5P £anking regulatory sequences.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
L-type Ca2þ channel K1C subunit (Cav1.2), encoded by
CACNA1C [1], is widely expressed and plays vital roles in
electrophysiology and excitation^contraction coupling. There
is important transcriptional regulation of cardiac Cav1.2.
Changed Cav1.2 expression is associated with cardiac arrhyth-
mias and congestive heart failure [2^4]. Alterations in Ca2þ
channel properties in developing rat hearts result from tran-
scriptionally regulated expression changes [5]. L-Adrenergic
stimulation increases Cav1.2 mRNA expression in neonatal
myocytes, followed by increased L-type Ca2þ current [6]. Pro-
tein kinase A regulates Cav1.2 expression in rat myocytes by
altering transcription rate [7]. The 5P £anking region of rat
CACNA1C shows several potential transcription factor (TF)
binding sites, including a putative cAMP response element,
which could mediate L-adrenergic e¡ects [8]. Recently, alter-
natively spliced ¢rst exons have been described in human
CACNA1C [9^11], with one isoform mainly expressed in the
heart and the other driven by a di¡erent promoter mainly
expressed in vascular muscle cells [10,11]. In this study, we
cloned these exons and their 5P £anking regions and studied
tissue-speci¢c expression.
2. Materials and methods
2.1. RNA and genomic DNA isolation
Total RNA was extracted from normal and failing human left
ventricle (LV), right ventricle, atrium and septum, human aorta vas-
cular smooth muscle cells (HA-VSMC) and HEK293 cells with TRI-
zol1 (Invitrogen). Human tissues were obtained from the Re¤seau de
tissus pour e¤tudes biologiques tissue bank under procedures approved
by the Human Research Ethics Committee of the Montreal Heart
Institute. Additional human RNA samples were purchased from
Clontech. Human genomic DNA was isolated from whole blood
with Promega Wizard Genomic DNA Puri¢cation kits.
2.2. Rapid ampli¢cation of cDNA ends (RACE)
The transcription start sites of human CACNA1C transcripts were
determined with Ambion’s RNA ligase-mediated 5PRACE kit. Gene-
speci¢c primers (GSPs) for 5PRACE were designed based on the hu-
man CACNA1C exon 2 (GenBank accession number Z26257): GSP1:
GTGGAGCTGACTGTGGAGATGGT; GSP2: CTGCCGCATTG-
GCATTCATGTTG. Polymerase chain reaction (PCR) products were
subcloned into PCR2.1 (Invitrogen) and sequenced.
2.3. Quanti¢cation of CACNA1C transcripts
TaqMan quantitative assay of CACNA1C transcripts was per-
formed with real-time two-step reverse transcription PCR (GeneAmp
5700, PE Biosystems), involving an initial reverse transcription with
random primers. Primers for real-time PCR crossed the junctions
of exon 1 (each alternative isoform) and exon 2: isoform A, for-
ward primer (FW): TGCCAACACGGAGGTCAAG, reverse primer
(REV): TTGGAACCTCCAGGAGAGATGT; isoform B, FW:
GGTCCATGGTCAATGAGAATACG, REV: GGCTCCCATAGT-
TGGAACCTT. Absolute quanti¢cation was obtained with the use of
a plasmid containing Exon 1A-2 and Exon 1B-2 sequences as a stan-
dard. Human GAPDH control reagents (Applied Biosystems) were
used as internal controls. Products of ampli¢cation were also veri¢ed
by gel electrophoresis and dissociation curve analysis with SYBR
green.
2.4. PCR ampli¢cation of putative promoter regions and construction of
promoter-luciferase fusion plasmids
PCR was performed with human genomic DNA as a template,
using Advantage and Advantage-GC genomic polymerase mixes
(Clontech). PCR primers were designed based on GenBank sequence
AC005342. Luciferase-containing constructs were purchased from
Promega. The PGL3 promoter contains the SV40 promoter element
(but not the enhancer) upstream of the luciferase gene and PGL3-
Basic includes only the luciferase gene with an upstream multiple
cloning site for introducing putative promoter fragments. PCR prod-
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ucts were subcloned into PCR2.1 ¢rst, and then cloned into the poly-
linker region of PGL3-Basic with appropriate restriction enzymes.
2.5. DNA sequencing and analysis
The integrity and orientation of all constructs were con¢rmed by
restriction endonuclease analysis and DNA sequencing. Results were
analyzed with BLAST and Clone Manager V6.0 (Sci-Ed). TF binding
sites were analyzed with MatInspector V2.2.
2.6. Cell culture
HA-VSMC were grown in modi¢ed F-12K medium (American
Type Culture Collection) containing 10% fetal bovine serum (FBS;
Invitrogen), 10 mM HEPES, 10 mM TES, 0.05 mg/ml L-ascorbic acid,
0.01 mg/ml insulin, 0.01 mg/ml transferrin, 10 ng/ml sodium selenite
and 0.03 mg/ml endothelial cell growth supplement. Cells in passage
22^24 were used for transfection. HEK293 cells were grown in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) containing 10% FBS.
H9C2 cells were grown in DMEM containing 10% FBS.
2.7. Neonatal rat cardiomyocyte culture
One- to 2-day-old rats were decapitated, hearts aseptically removed,
dissected, minced, and exposed overnight to 0.05% trypsin (4‡C). The
next day, cells were dissociated with collagenase (Worthington), cen-
trifuged (500Ug, 4‡C), and pre-plated in culture £asks (60 min, 37‡C).
Subsequently, non-attached cells (myocytes) were plated on 24-well
plates in DMEM/F-12 medium (Invitrogen) containing 10% FBS,
0.1 mM L-ascorbic acid, 0.1 mM bromodeoxyuridine (Sigma), insu-
lin^transferrin^sodium selenite (Invitrogen) and 1039 M triiodothy-
ronine. Over 90% of cells in culture were observed to beat.
2.8. Neonatal ¢broblast culture
Neonatal rat cardiac ¢broblasts were prepared as for cardiomyo-
cytes, with adherent cells obtained during the pre-plating procedure
cultured in the same medium but without bromodeoxyuridine. Cells
were maintained to con£uence and then plated in 24-well plates for
transfection.
2.9. Transfection and luciferase assay
Cells were transfected with 1 Wg PGL3-target DNA (¢re£y lucifer-
ase vector) and 0.1 Wg PRL-TK (TK-driven Renilla luciferase expres-
sion vector, a control for transfection e⁄ciency, Promega) with Lipo-
fectamine-2000 (Invitrogen). Following transfection (48^72 h), cells
were washed with phosphate-bu¡ered saline and lysed with 150 Wl
passive lysis bu¡er (Promega). Luciferase activity was measured
with a dual luciferase reporter assay kit (Promega) on a Lumat
LB9507 luminometer.
2.10. Statistics
Each experiment was performed in triplicate. Reported values rep-
resent the mean of three to ¢ve separate experiments. Results are
meanTS.E.M., and statistical comparison was by Student’s t-test.
3. Results
3.1. 5PRACE results
Two isoforms were de¢ned by 5PRACE (Fig. 1). Isoform A
(524 bp) contains a 3P 57-bp sequence identical with CAC-
NA1C exon 2 (Z26257). The following 467-bp region, identi-
cal to part of the human 12p13.3 P1-derived arti¢cial chro-
mosome RP5-1096D14 sequence (AC005342), will be termed
exon 1A. Isoform B (660 bp) was obtained based on two
products (647 and 660 bp), identical except for 13 bp at the
5P end. The 3P 57-bp region is identical to CACNA1C exon 2
(Z26257) and the following 420-bp region is identical to CAC-
NA1C exon 1 (Z26256). The 603-bp 5P sequence is identical to
the corresponding sequence of AC005342 and will be termed
exon 1B. The ¢rst two exon^intron junctions meet the de¢ni-
tion of ‘donor site’ sequences: AG-gt. The 5PRACE products
correspond to sequences in human chromosome 12 working
draft sequence segment NT_024408, containing the CAC-
NA1C gene.
3.2. Tissue and regional distribution
Isoform A was strongly expressed in heart (Fig. 2A). For
non-cardiac tissues, only uterus and adrenal gland showed
signi¢cant concentrations of isoform A transcripts (Fig. 2A).
Isoform B was expressed across a broad range of tissues and
cell types (Fig. 2B). In all non-cardiac tissues, isoform B/A
transcript concentration ratios exceeded 1, with ratios of tran-
script B to A at least 8:1 (Fig. 2C).
Fig. 1. 5PRACE results and proposed gene structure. Two 5PRACE products and nucleotide homology with reported GenBank sequences. The
two junctions of ¢rst exon^intron boundaries meet the de¢nition of ‘donor site’ sequences. The location and sizes of exons and introns are ac-
cording to GenBank: NT_024408.
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Isoform A transcript concentrations were highest in LV free
wall (Fig. 2D). Isoform B/A transcript concentration ratios
were consistent at V0.1 across regions (Fig. 2E). Transcript
levels for both isoforms were reduced in failing LV (Fig. 2F),
without change in relative expression.
3.3. 5P upstream regions
Putative cis-acting regulatory elements in the sequences im-
mediately upstream of exon 1A and exon 1B were analyzed.
The putative CACNA1C promoter A had no apparent TATA
element and was not GC-rich, but there was an ‘initiator’ (5P-
Py-Py-A-N-A/T-Py-Py, Py=C/T) sequence [12]. Unlike GC-
rich promoters, such promoters are usually not constitutively
active [12]. The putative CACNA1C promoter B contained
features of ‘housekeeping-type promoters’ : absence of
TATA or CAAT boxes, presence of several GC-rich Sp1 con-
sensus elements.
3.4. Promoter activity
CACNA1C promoter-luciferase fusion plasmids were tran-
siently transfected into neonatal cardiomyocytes, cardiac ¢-
broblasts, H9C2, HA-VSMC, and HEK293 cells. The activ-
ities of promoter A constructs in cardiomyocytes were ¢ve- to
nine-fold of PGL-basic, with substantial activity in the 3436/
+80 region and detectable further activity in the region be-
tween 31393 and 31062 (Fig. 3B). Promoter A constructs
failed to show activity in any non-cardiomyocyte cell types
(Fig. 3C^F). Promoter B had substantial activity in all cell
types (Fig. 4B^F). The inclusion of nucleotides 31727 to
3613 reduced promoter activity, suggesting negative regula-
tory elements.
Cardiac-speci¢c activity of promoter A was maintained in
the shortest (3436/+80) construct studied (Fig. 3). We com-
pared potential TFs in this region between promoter A and
the corresponding rat promoter (which drives expression in
vascular tissue [8]) and found that promoter A possesses
unique Nkx2.5 (3223) and E box (+30) elements. We exam-
ined the e¡ects of their mutation (Nkx2.5: from AACTTGA
to AGCTCAG; E box: from CACTGG to GGATTG) on
activity of the PGL3-(3436/+80) construct in neonatal rat
cardiomyocytes and HA-VSMC. Wild-type PGL3-(3436/
+80) showed luciferase activity 8.85 T 1.36-fold that of
PGL3-Basic in atrial cells and 7.17T 0.52-fold in ventricular
cells, versus 1.13T 0.08-fold in HA-VSMC (7.8- and 6.3-fold
cardiac selectivity for atrium and ventricle versus HA-VSMC
respectively). Mutation of the Nkx2.5 sequence resulted in
5.09T 0.21- and 4.35T 0.40-fold activity in atrial and ventric-
ular myocytes, compared to 0.84T 0.15 in HA-VSMC (6.0-
and 5.2-fold cardiac selectivity in atrium and ventricle). Mu-
tation of the E box resulted in 4.90T 0.17-fold activity in
atrial and 3.00T 0.52 in ventricular myocytes, versus
1.01T 0.07 in HA-VSMC (4.8- and 3.0-fold cardiac selectiv-
ity).
4. Discussion
We have identi¢ed alternative CACNA1C exon 1 isoforms
in the human genome, cloned their respective 5P upstream
regions and shown di¡erences in potential regulatory elements
that correspond to di¡erences in tissue-speci¢c expression.
The relative expression of these isoforms is consistent across
regions in the human heart and is una¡ected by congestive
Fig. 2. Isoform distribution with tissue and disease. A: Isoform A
expression in di¡erent tissues and cell types. B: Isoform B expres-
sion in di¡erent tissues and cell types. C: Isoform B/A expression
ratios. D: Absolute isoform expression in di¡erent regions of nor-
mal hearts (n=4). E: Isoform B/A ratios in di¡erent cardiac re-
gions. F: Isoform expression in congestive heart failure. NLV, nor-
mal left ventricle (n=6); HFLV, failing LV (n=7).
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heart failure, although the expression of both is down-regu-
lated in the failing heart.
Recently, a longer N-terminal Cav1.2 isoform di¡erentially
regulated by protein kinase C has been described in human
heart [9]. This isoform is encoded by exon 1A, which we
found to show cardiac-selective expression, emphasizing its
importance. Along with previous observations [10,11], our
results support the arguments of Blumenthal et al. [9] for
the potential importance of the long N-terminal variant in
the human heart.
The N-terminal-encoding Cav1.2 cDNAs of rabbit heart
[13] and rat aorta [14] share 80% and 69% residue identity
with human isoform A. The rat CACNA1C promoter [8]
has 51% residue identity with human promoter A (31494 to
+80). The rat promoter is active in pulmonary artery vascular
smooth muscle cells [8], whereas promoter A is inactive in
HA-VSMC. Our mutation studies suggested that some of
the di¡erences in cardiac selectivity between the rat and hu-
man promoters may be due to speci¢c Nkx2.5 and E box
sequences present only in the human promoter. A recent pa-
per reported that a c-Ets-like motif (CAGGATGC) is essen-
tial for rat CACNA1C promoter activity in vascular smooth
muscle cells [15]. In the corresponding region (3622) of hu-
man promoter A, the sequence di¡ers slightly from the rat
Ets-like motif, but deletion of this region in promoter A did
not alter cardiac speci¢city (Fig. 3B). Ca2þ channel K1C sub-
unit cDNAs from rabbit vascular smooth muscle [16] and rat
brain [17] share 80% and 75% residue identity with human
isoform B, consistent with our ¢ndings regarding isoform B
expression patterns.
H9C2 is a clonal cardiac cell line derived from embryonic
rat heart [18] and expresses L-type Ca2þ currents with cardiac
characteristics [19]. We were surprised that human CAC-
NA1C promoter A had no promoter activity in H9C2 cells.
However, H9C2 cells also express skeletal muscle L-type Ca2þ
channels [20], consistent with a phenotype that is not cardiac-
speci¢c.
The rat and cat ncx1 genes [21,22] encoding Naþ,Ca2þ-ex-
changer isoform 1 also have alternative promoters which con-
trol tissue distribution. These genes are similar to CACNA1C:
the alternative ¢rst exons spread out over a large genomic
region, a cardiac-speci¢c promoter regulates the heart-speci¢c
isoform expression, transcription begins at an ‘initiator’ se-
quence and GATA box, E box and AP1 binding sites are
present in the proximal promoter region. For both, the ubiq-
uitously expressed isoform is strongly expressed in brain and
is controlled by a housekeeping-type promoter.
There is growing evidence for Cav1.2 subunit diversity aris-
ing from alternative splicing of a primary transcript [10,11,23].
In this study, we show the existence of N-terminal variability
in human Cav1.2 subunits and tissue-selective control by al-
ternative promoters. This work provides a basis for further
studies of factors controlling local Cav1.2 expression under
C
Fig. 3. Promoter A activity in various cell types. Open bars, nega-
tive control (PGL3-basic); solid bars, positive control (SV40 pro-
moter); hatched bars, promoter A-luciferase fusion plasmid con-
structs. Nucleotides of fusion plasmids are numbered with respect to
the transcription start site (+1) identi¢ed by 5PRACE that is 55 nu-
cleotides upstream of the transcription start site identi¢ed in [10].
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physiological and pathological conditions. Alternatively
spliced C-terminal exons have also been reported to show
tissue-speci¢c expression [23]. Further studies of the role of
various alternatively spliced Cav1.2 isoforms and potential
interactions between them would be interesting.
We found Cav1.2 mRNA to be down-regulated by heart
failure. Many investigators have studied L-type Ca2þ current
and corresponding Cav1.2 changes in experimental and clin-
ical heart failure (for review, see [24]). The results have been
variable, with the majority of studies showing a decrease and
a signi¢cant number of studies showing no change. The var-
iability is likely due to di¡erences in the degree and mecha-
nism of heart failure, limited sample sizes and (in clinical
studies) the role of concomitant drug therapy, patient factors
such as age, sex and ethnic di¡erences, etc. It is interesting
that despite signi¢cant down-regulation of CACNA1C expres-
sion, the isoform A/B ratio remained unchanged in failing
hearts in the present study, suggesting the factors that drive
strong cardiac-selective expression of isoform A and weaker
cardiac expression of isoform B are not signi¢cantly altered by
the important metabolic, structural, signaling and regulatory
alterations in congestive heart failure.
Acknowledgements: The authors thank the Canadian Institutes of
Health Research for funding and France The¤riault for secretarial
help.
References
[1] Ertel, E.A., Campbell, K.P., Harpold, M.M., Hofmann, F.,
Mori, Y., Perez-Reyes, E., Schwartz, A., Snutch, T.P., Tanabe,
T., Birnbaumer, L., Tsien, R.W. and Catterall, W.A. (2000) Neu-
ron 25, 533^535.
[2] Brundel, B.J., van Gelder, I.C., Henning, R.H., Tuinenburg,
A.E., Deelman, L.E., Tieleman, R.G., Grandjean, J.G., van
Gilst, W.H. and Crijns, H.J. (1999) Cardiovasc. Res. 42, 443^
454.
[3] Van Wagoner, D.R., Pond, A.L., Lamorgese, M., Rossie, S.S.,
McCarthy, P.M. and Nerbonne, J.M. (1999) Circ. Res. 85, 428^
436.
[4] Takahashi, T., Allen, P.D., Lacro, R.V., Marks, A.R., Dennis,
A.R., Schoen, F.J., Grossman, W., Marsh, J.D. and Izumo, S.
(1992) J. Clin. Invest. 90, 927^935.
[5] Liu, L., O’Hara, D.S., Cala, S.E., Poornima, I., Hines, R.N. and
Marsh, J.D. (2000) Mol. Cell. Biochem. 205, 101^109.
[6] Maki, T., Gruver, E.J., Davido¡, A.J., Izzo, N., Toupin, D.,
Colucci, W., Marks, A.R. and Marsh, J.D. (1996) J. Clin. Invest.
97, 656^663.
[7] Fan, I.Q., Chen, B. and Marsh, J.D. (2000) J. Mol. Cell. Cardiol.
32, 1841^1849.
[8] Liu, L., Fan, Q.I., El Zaru, M.R., Vanderpool, K., Hines,
R.N. and Marsh, J.D. (2000) Am. J. Physiol. 278, H1153^
H1162.
[9] Blumenstein, Y., Kanevsky, N., Sahar, G., Barzilai, R., Ivanina,
T. and Dascal, N. (2002) J. Biol. Chem. 277, 3419^3423.
[10] Dai, B., Saada, N., Echetebu, C., Dettbarn, C. and Palade, P.
(2002) Biochem. Biophys. Res. Commun. 296, 429^433.
[11] Saada, N., Dai, B., Echetebu, C., Sarna, S.K. and Palade, P.
(2003) Biochem. Biophys. Res. Commun. 302, 23^28.
[12] Smale, S.T. and Baltimore, D. (1989) Cell 57, 103^113.
[13] Mikami, A., Imoto, K., Tanabe, T., Niidome, T., Mori, Y.,
Takeshima, H., Narumiya, S. and Numa, S. (1989) Nature 340,
230^233.
[14] Koch, W.J., Ellinor, P.T. and Schwartz, A. (1990) J. Biol. Chem.
265, 17786^17791.
[15] Fan, Q.I., Vanderpool, K. and Marsh, J.D. (2002) Biochim. Bio-
phys. Acta 1577, 401^411.
[16] Biel, M., Ruth, P., Bosse, E., Hullin, R., Stuhmer, W., Flockerzi,
V. and Hofmann, F. (1990) FEBS Lett. 269, 409^412.
[17] Snutch, T.P., Tomlinson, W.J., Leonard, J.P. and Gilbert, M.M.
(1991) Neuron 7, 45^57.
[18] Kimes, B.W. and Brandt, B.L. (1976) Exp. Cell Res. 98, 367^
381.
Fig. 4. Promoter B activity in various cell types. Open bars, nega-
tive control (PGL3-basic); solid bars, positive control (SV40 pro-
moter); hatched bars, promoter B-luciferase fusion plasmid con-
structs. Nucleotides of fusion plasmids are numbered with respect to
the 3P transcription start site (+1) identi¢ed by 5PRACE.
FEBS 27390 18-6-03
L. Pang et al./FEBS Letters 546 (2003) 349^354 353
[19] Hescheler, J., Meyer, R., Plant, S., Krautwurst, D., Rosenthal,
W. and Schultz, G. (1991) Circ. Res. 69, 1476^1486.
[20] Mejia-Alvarez, R., Tomaselli, G.F. and Marban, E. (1994)
J. Physiol. 478, 315^329.
[21] Barnes, K.V., Cheng, G., Dawson, M.M. and Menick, D.R.
(1997) J. Biol. Chem. 272, 11510^11517.
[22] Nicholas, S.B., Yang, W., Lee, S.L., Zhu, H., Philipson, K.D.
and Lytton, J. (1998) Am. J. Physiol. 274, H217^H232.
[23] Soldatov, N.M. (1994) Genomics 22, 77^87.
[24] Tomaselli, G.F. and Marban, E. (1999) Cardiovasc. Res. 42,
270^283.
FEBS 27390 18-6-03
L. Pang et al./FEBS Letters 546 (2003) 349^354354
